罗格列酮逆转人胃癌祼鼠移植瘤对丝裂霉素耐药的作用  

The Effect of Reversing the Resistance to Mitomycin in Nude Mice Xenografts of Human Gastric Carcinoma by Rosiglitazone

作　　者：廖文秋[1] 张琍[1] 李国庆[1] 

机构地区：[1]南华大学第二附属医院消化内科,湖南衡阳421001

出　　处：《中南医学科学杂志》2011年第1期58-61,共4页Medical Science Journal of Central South China

基　　金：湖南省卫生厅资助项目(2007110);湖南省自然科学基金资助项目(08JJ5002);湖南省科技厅资金资助项目(2009SK3138)

摘　　要：目的观察PPARγ激动剂罗格列酮(ROS)能否逆转人胃癌SGC7901/VCR细胞裸鼠移植瘤对丝裂霉素(MMC)的耐药作用。方法建立人胃癌SGC7901/VCR细胞裸鼠移植瘤模型,将48只裸鼠随机分为6组:空白对照组(生理盐水0.2 mL灌胃)、MMC组(MMC 2.5 mg/kg腹腔注射)、ROS组(ROS100 mg/kg灌胃)、MMC+ROS中剂量组(MMC2.5 mg/kg腹腔注射+ROS 50 mg/kg灌胃)、MMC+ROS高剂量组(MMC 2.5 mg/kg腹腔注射+ROS 100 mg/kg灌胃)、MMC+CSA组(MMC2.5 mg/kg腹腔注射+CSA 50 mg/kg灌胃)。每组8只裸鼠;用药40天后,观察各组裸鼠体重和移植瘤体积变化,计算抑瘤率,绘制移植瘤的生长曲线;HE染色观察移植瘤的组织形态。结果处死前各组裸鼠体重差异无统计学意义(P>0.05);空白对照组、MMC组移植瘤瘤体积和抑瘤率差异无显著性(P>0.05),ROS组、MMC+ROS中剂量组、MMC+ROS高剂量组、MMC+CSA组与空白对照组、MMC组比较移植瘤瘤体积和抑瘤率差异均有显著性(P<0.05)。结论罗格列酮可抑制人胃癌SGC7901/VCR细胞祼鼠移植瘤瘤体生长,罗格列酮可部分逆转人胃癌SGC7901/VCR细胞祼鼠移植瘤对丝裂霉素的耐药性。Objective To explore whether Rosiglitazone（ROS）,a selective Peroxisome proliferator-activated receptor gamma（PPARγ） ligand,can reverse the resistance to Mitomycin（MMC） of human gastric cancer SGC7901/VCR cell transplanted into mice which has multidrug resistant phenotype.Methods The model of xenografts tumor in nude mice were established by inoculating human gastric cancer cells line SGC7901/VCR into the back of nude mice subcutaneously.Forty-eight male nude mice were divided into six groups：Control group,MMC group,ROS group,MMC combined moderate dose ROS group,MMC combined high dose ROS group,MMC combined cyclosporineA（CSA） group.There were eight mice in each group.After treated for forty days,the volume changes of tumor and tumor inhibition rates were observed,the growth curve of xenograft tumor was drawn.Morphology of the xenograft tumor was observed by HE stain.Results The difference of the average transplantable tumor weight in the Control group and other groups were not statistically different before executed（P0.05）.After medication the effect on the volume of transplantable tumor and tumor inhibition rates：there was no significant difference between Control group and MMC group（P0.05）,the difference of tumor volume and tumor inhibition rates were significant between other groups compared with Control group and MMC group（P0.05）.Conclusioins Rosiglitazone inhibits the growth of tralantabletumor of SGC7901/VCR cell.Rosiglitazone can reserve the drug resistance of transplantable tumor of SGC7901/VCR cell to MMC partly in vivo.

关 键 词：PPARΓ 罗格列酮 多药耐药 SGC7901/VCR细胞株 

分 类 号：R735.2[医药卫生—肿瘤]